Developer docs
API playgroundTry for free, no card

Search company profiles

Mithra Pharmaceuticals

Full company profile

uuid00054ow

Namestring
Mithra Pharmaceuticals
Legal namestring
Mithra Pharmaceuticals SA
Websiteurl
mithra.com
Company typeenum
Private
Founded yearint
1999
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersLiège, Belgium
HQ citystring
Liège
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
women's health pharmaceuticals, hormonal contraception, menopause therapy, biopharmaceutical products, hormone replacement therapy
Industry2 codes
1Women’s Health & Reproductive Specialty Pharmaceuticals
CodeHLAIACANPrimaryYes
2Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
CodeHLAIAAAJPrimaryNo
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Women's Health Pharmaceuticals
Social media profiles1 record
Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Mithra Pharmaceuticals is a Belgian biopharmaceutical company that develops and commercializes pharmaceutical products focused exclusively on women's health. Its portfolio targets two therapeutic areas: hormonal contraception and menopause/hormone replacement therapy (HRT), with named assets such as Donesta® under development for menopause treatment.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Mithra is an AI-native Enterprise Marketing OS — a unified platform combining four integrated disciplines: Acquisition (paid media optimization), Lifecycle (agent-driven automation), CDP (managed data pipelines), and Analytics (AI insights and reporting). The platform centers on the M1 reasoning model, a proprietary marketing-specific AI fine-tuned on 2.4B first-party events with 128K token context. E1 serves as the Customer Data Platform foundation. M1 and E1 operate across all four disciplines to deliver autonomous campaign management, predictive segmentation, and real-time optimization. The platform is designed for enterprise marketing organizations requiring AI-powered decision-making at scale.

Product and service1 record
1Donesta®
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Gedeon Richter
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Gedeon Richter acquired Estetra and Neuralis from Mithra Pharmaceuticals. This represents a strategic divestiture of certain business units by Mithra to Gedeon Richter, a pharmaceutical company.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
1Gedeon Richter Plc.
TypeDirect peer
Description

Hungarian-headquartered pharma group with a major women's health franchise (contraception, HRT) and the acquirer of Mithra's Estetra and Neuralis units, making it a direct strategic peer and counterparty.

2Bayer AG (Pharmaceuticals Division)
TypeBroad incumbent
Description

Large pharmaceutical incumbent with leading women's health franchises including Mirena hormonal IUD and Yaz/Yasmin oral contraceptives, directly overlapping with Mithra's contraception and IUD focus areas.

3Endo International plc
TypeBroad incumbent
Description

Specialty pharma with women's health and endocrinology exposure (e.g., menopausal hormone therapies), overlapping with Mithra's HRT and reproductive health focus.

4Amneal Pharmaceuticals, Inc.
TypeBroad incumbent
Description

Generic and specialty pharmaceutical manufacturer with exposure to women's health and hormone therapy categories, including generic oral contraceptives.

5Organon & Co.
TypeDirect peer
Description

Pure-play women's health pharmaceutical company spun out of Merck, offering contraception, fertility, and menopause therapies. Closest publicly traded comparable given its exclusive focus on women's health and similar therapeutic portfolio.

6AbbVie Inc.
TypeBroad incumbent
Description

Major diversified pharma with women's health exposure (e.g., Lo Loestrin Fe, Orilissa) and significant commercial reach, competing in the same therapeutic areas with broader resources.

7Pfizer Inc.
TypeBroad incumbent
Description

Global pharmaceutical incumbent with established women's health and contraceptive franchises, competing with Mithra in contraception and HRT markets.

8Daré Bioscience, Inc.
TypeEmerging player
Description

Clinical-stage biopharmaceutical company developing women's health products across contraception, menopause, and reproductive health, with comparable therapeutic focus to Mithra.

9Agile Therapeutics, Inc.
TypeEmerging player
Description

Smaller women's health company focused on hormonal contraceptive products (Twirla patch), competing in the contraceptive segment with Mithra.

10TherapeuticsMD, Inc.
TypeDirect peer
Description

US women's health company commercializing hormone therapy and contraceptive products (e.g., Bijuva, Annovera). Operates in overlapping menopause/HRT and contraception categories.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mithra Pharmaceuticals

Women's Health Pharmaceuticalsmithra.com

Mithra Pharmaceuticals firmographics

Firmographics
Name
Mithra Pharmaceuticals
Legal name
Mithra Pharmaceuticals SA
Website
https://mithra.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
251–500 employees
Ownership category
akta.pro rank

Mithra Pharmaceuticals industry classification

Industry
Product category
Women's Health Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro primary industry
Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN)
akta.pro secondary industry
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

  • Women's health pharmaceuticals
  • Hormonal contraception
  • Menopause therapy
  • Biopharmaceutical products
  • Hormone replacement therapy

Where Mithra Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Liège
HQ country
Belgium
HQ region
Europe

Markets served

Mithra Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Mithra Pharmaceuticals product offering

Product offering

Core offering

Mithra Pharmaceuticals is a Belgian biopharmaceutical company that develops and commercializes pharmaceutical products focused exclusively on women's health. Its portfolio targets two therapeutic areas: hormonal contraception and menopause/hormone replacement therapy (HRT), with named assets such as Donesta® under development for menopause treatment.

Product overview

Mithra is an AI-native Enterprise Marketing OS — a unified platform combining four integrated disciplines: Acquisition (paid media optimization), Lifecycle (agent-driven automation), CDP (managed data pipelines), and Analytics (AI insights and reporting). The platform centers on the M1 reasoning model, a proprietary marketing-specific AI fine-tuned on 2.4B first-party events with 128K token context. E1 serves as the Customer Data Platform foundation. M1 and E1 operate across all four disciplines to deliver autonomous campaign management, predictive segmentation, and real-time optimization. The platform is designed for enterprise marketing organizations requiring AI-powered decision-making at scale.

Differentiator

Problem solved

Functional benefit

Products and services

  • Donesta®

Companies that use Mithra Pharmaceuticals

Customer profile

Segments3 records

Ideal customer profiles3 records

Mithra Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Mithra Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Gedeon RichtermajorStrategic or Co-development PartnerGedeon Richter acquired Estetra and Neuralis from Mithra Pharmaceuticals. This represents a strategic divestiture of certain business units by Mithra to Gedeon Richter, a pharmaceutical company.

Scale indicators3 records

Recent moves6 records

Expansion highlights3 records

Mithra Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Gedeon Richter Plc. Hungarian-headquartered pharma group with a major women's health franchise (contraception, HRT) and the acquirer of Mithra's Estetra and Neuralis units, making it a direct strategic peer and counterparty.
  • Organon & Co. Pure-play women's health pharmaceutical company spun out of Merck, offering contraception, fertility, and menopause therapies. Closest publicly traded comparable given its exclusive focus on women's health and similar therapeutic portfolio.
  • TherapeuticsMD, Inc. US women's health company commercializing hormone therapy and contraceptive products (e.g., Bijuva, Annovera). Operates in overlapping menopause/HRT and contraception categories.

Broad incumbents

  • Bayer AG (Pharmaceuticals Division): Large pharmaceutical incumbent with leading women's health franchises including Mirena hormonal IUD and Yaz/Yasmin oral contraceptives, directly overlapping with Mithra's contraception and IUD focus areas.
  • Endo International plc: Specialty pharma with women's health and endocrinology exposure (e.g., menopausal hormone therapies), overlapping with Mithra's HRT and reproductive health focus.
  • Amneal Pharmaceuticals, Inc. Generic and specialty pharmaceutical manufacturer with exposure to women's health and hormone therapy categories, including generic oral contraceptives.
  • AbbVie Inc. Major diversified pharma with women's health exposure (e.g., Lo Loestrin Fe, Orilissa) and significant commercial reach, competing in the same therapeutic areas with broader resources.
  • Pfizer Inc. Global pharmaceutical incumbent with established women's health and contraceptive franchises, competing with Mithra in contraception and HRT markets.

Emerging players

  • Daré Bioscience, Inc. Clinical-stage biopharmaceutical company developing women's health products across contraception, menopause, and reproductive health, with comparable therapeutic focus to Mithra.
  • Agile Therapeutics, Inc. Smaller women's health company focused on hormonal contraceptive products (Twirla patch), competing in the contraceptive segment with Mithra.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Mithra Pharmaceuticals social profiles

Digital presence

Mithra Pharmaceuticals compliance and trust

Trust signal

Compliance3 records

Mithra Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mithra Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles2 records

Mithra Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mithra Pharmaceuticals M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mithra Pharmaceuticals

What does Mithra Pharmaceuticals do?

Mithra Pharmaceuticals is a Belgian biopharmaceutical company that develops and commercializes pharmaceutical products focused exclusively on women's health. Its portfolio targets two therapeutic areas: hormonal contraception and menopause/hormone replacement therapy (HRT), with named assets such as Donesta® under development for menopause treatment.

Is Mithra Pharmaceuticals a public or private company?

Mithra Pharmaceuticals is a private company. It is classified as public and is currently operating.

When was Mithra Pharmaceuticals founded?

Mithra Pharmaceuticals was founded in 1999. It employs 251 to 500 people.

Where is Mithra Pharmaceuticals based?

Mithra Pharmaceuticals is headquartered in Liège, Belgium, in the Europe region.

Who are Mithra Pharmaceuticals's main competitors?

Direct peers on record are Gedeon Richter Plc., Organon & Co. and TherapeuticsMD, Inc.. Broad incumbents are Bayer AG (Pharmaceuticals Division), Endo International plc, Amneal Pharmaceuticals, Inc., AbbVie Inc. and Pfizer Inc.. Emerging players are Daré Bioscience, Inc. and Agile Therapeutics, Inc..

Does Mithra Pharmaceuticals have an API?

No public API is recorded for Mithra Pharmaceuticals.

What industry is Mithra Pharmaceuticals in?

Mithra Pharmaceuticals's product category is Women's Health Pharmaceuticals. Its primary akta.pro industry code is HLAIACAN, Women’s Health & Reproductive Specialty Pharmaceuticals, with a secondary code of HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GedeonrichterRichter agreed to acquire certain assets from Mithra PharmaceuticalsGedeon Richter Plc. has completed the acquisition of assets from Mithra Pharmaceuticals SA and its subsidiaries for an enterprise value of EUR 175 million, including 100% shares in Estetra SRL and Neuralis SA. The deal grants Richter exclusive worldwide rights to the Estetrol (E4) platform and associated products, aiming to expand its presence in the global Women’s Healthcare market. This strategic move allows Richter to establish original gynaecological research capabilities and enter new geographic markets such as the US and Japan.GedeonrichterRichter agreed to acquire certain assets from Mithra PharmaceuticalsRichter has agreed to acquire certain assets from Mithra Pharmaceuticals. The article provides a reference code for the transaction details but does not specify the nature of the assets or financial terms. No further strategic implications or background context are provided in the text.GlobeNewswireMithra postpones its annual general meetingMithra Pharmaceuticals has postponed its Annual General Shareholders' Meeting, originally scheduled for 30 May 2024, citing uncertainties related to its ongoing monetization process. The company is currently undergoing judicial reorganization proceedings in Belgium, involving the sale of assets like Estetra SRL and a debt restructuring plan for its Novalon SA subsidiary under court protection.GlobeNewswireMithra sells shares in Mayne PharmaMithra sold all 4,221,815 Mayne Pharma shares for A$5.03 each, netting A$21.1 million. Proceeds will prepay loans and/or operational purposes, held in escrow pending lender agreement. The sale follows Mithra's February 6 cash position announcement.GlobeNewswireMithra Completes Pediatric Study of ESTELLE® in Adolescent PatientsMithra completed a pediatric study of its contraceptive ESTELLE in over 100 adolescents aged 12-17, with data expected in Q2 2024. The study, conducted under an EMA Pediatric Investigation Plan, aims to evaluate safety and could lead to a six-month extension of the Supplementary Protection Certificate.GlobeNewswireMithra’s NEXTSTELLIS® granted additional patent in the United StatesMithra Pharmaceuticals announced it was granted an additional US patent for its contraceptive NEXTSTELLIS, extending protection until 2036. The patent is a continuation of U.S. Patent No. 11,147,771, and Mayne Pharma holds the US license. The company expects the extension to add seven years of peak sales opportunities.GlobeNewswireMithra releases invitation to its extraordinary securities holders’ meetingMithra Pharmaceuticals issued an invitation to its extraordinary securities holders' meeting, scheduled for Thursday, 23 November 2023 at 2:00 PM CET. Shareholders must register by 17 November 2023 to vote, and questions can be submitted in writing by the same deadline.GlobeNewswireShareholder LetterMithra Pharmaceuticals' board responded to a shareholder group holding 6.1% of shares requesting termination of four independent board members. The group, including Uteron Sellers, seeks to lift a EUR 185 million nominal obligation, valued at EUR 82.6 million. The company maintains its position and will continue to act in shareholders' best interests.GlobeNewswireMithra présentera ses résultats financiers du premier semestre 2023 à ses investisseurs lors d'une conférence web le 26 septembre à 14 h 00 CETMithra Pharmaceuticals will present its Q2 2023 financial results via a web conference on September 26 at 14:00 CET. The company, based in Liège, specializes in women's health and is developing Estetrol-based products, including the contraceptive Estelle and the new Donesta.GlobeNewswireInformation on the total number of voting rights (denominator)Mithra Pharmaceuticals announced a capital increase of 521,339 new shares, raising EUR 1,157,143.13 from a loan facility with Highbridge and Whitebox. The outstanding principal of drawn loans is EUR 60,360,161.29, and the total voting rights denominator is now 69,108,397.